

Pleural Effusion Epidemiology Forecast 2025-2034

Market Report | 2025-05-12 | 150 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$2699.00
- Five User License \$3739.00
- Corporate License \$4929.00

Report description:

Pleural Effusion Epidemiology Forecast 2025-2034

Determining the exact incidence of pleural effusion is challenging, as it is typically a symptom of an underlying condition. In the United States, it is estimated that nearly 1.5 million cases occur annually, with the majority being attributed to bacterial pneumonia, pulmonary embolism, congestive heart failure, and cancer.

Pleural Effusion Epidemiology Forecast Report Coverage

The Pleural Effusion Epidemiology Forecast Report 2025-2034 by Expert Market Research delivers a comprehensive analysis of the condition's prevalence and associated demographic factors. It projects future incidence and prevalence trends across diverse population groups, considering key variables such as age, gender, and pleural effusion type. The report highlights change in prevalence over time and offers data-driven forecasts based on influencing factors. Additionally, it provides an in-depth overview of the disease, along with historical and projected epidemiological data for eight key markets: the United States, United Kingdom, France, Italy, Spain, Germany, Japan, and India.

Pleural Effusion: Disease Overview

Pleural effusion is the accumulation of fluid in the pleural space surrounding the lungs. It can occur due to various underlying conditions, such as bacterial pneumonia, pulmonary embolism, congestive heart failure, and malignancy. Symptoms may include difficulty breathing, chest pain, and coughing. The condition is often diagnosed through imaging tests like chest X-rays or ultrasounds. Treatment depends on the underlying cause and may involve draining the fluid, addressing the primary condition, or medications. Pleural effusion can significantly affect lung function and quality of life if left untreated.

Epidemiology Overview

The epidemiology section of pleural effusion provides insights into the patient population from historical to current data, along with projected trends across eight major markets. Expert Market Research offers both current and future trends for pleural effusion by analysing numerous studies. The report also details the diagnosed patient pool and their trends, segmented into categories such as total diagnosed cases across various age groups and patient populations.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Globally, approximately 3,000 people per million are affected by pleural diseases, including tuberculous pleural effusion, malignant pleural effusion, and parapneumonic effusion. Around 150,000 new malignant pleural effusion cases are reported annually, with lung and breast cancers accounting for over 60% of them.

- The global incidence of malignant pleural effusion is approximately 660 per million people. Pleural effusion occurs equally in both sexes, though about two-thirds of malignant cases are in women, commonly linked to breast and gynecologic cancers.

Pleural Effusion: Treatment Overview

Pleural effusion treatment is focused on addressing the underlying cause and providing symptom relief. Treatment strategies depend on the type of pleural effusion, whether it's related to infections, heart failure, or malignancy. Common approaches include drainage of the fluid, medications, and occasionally surgical intervention. The goal is to reduce symptoms, prevent recurrence, and manage the underlying condition effectively.

1. Thoracentesis

Thoracentesis involves inserting a needle into the pleural space to remove excess fluid. It provides immediate relief from symptoms such as shortness of breath and chest pain. The procedure also allows for diagnostic analysis of the fluid to identify the underlying cause, whether infection, cancer, or heart failure.

2. Diuretics

In cases where pleural effusion is due to heart failure, diuretics are used to reduce fluid accumulation. These medications help remove excess fluid from the body, easing symptoms and preventing the effusion from recurring. They are typically administered orally or intravenously, depending on the severity of the condition.

3. Chest Tube Drainage

A chest tube may be inserted to drain large or recurrent pleural effusions. This approach is typically used when pleural effusion is caused by more severe conditions, such as cancer or infections, requiring continuous fluid drainage. Chest tube drainage may be used in conjunction with other treatments, such as antibiotics or chemotherapy.

4. Pleurodesis

Pleurodesis is a procedure used to prevent recurrent pleural effusion, particularly in patients with malignant pleural effusion. A sclerosing agent is introduced into the pleural space to cause irritation and fibrosis, effectively sealing the pleura and preventing further fluid buildup. This procedure is often done after drainage to reduce the chances of the effusion returning.

5. Oxygen Therapy

For patients with pleural effusion causing significant breathing difficulties, oxygen therapy may be administered to improve oxygen levels in the blood. This is typically used in conjunction with other treatments to manage symptoms and support the patient's respiratory function while addressing the underlying cause of the effusion.

Pleural Effusion: Burden Analysis

Pleural effusion, a condition where fluid accumulates in the pleural space around the lungs, significantly impacts the quality of life of affected individuals. It leads to symptoms such as shortness of breath, chest pain, and fatigue, which impair daily activities and reduce physical endurance. Patients often experience anxiety and discomfort due to respiratory difficulties, and in severe cases, pleural effusion can be life-threatening. Chronic or recurrent pleural effusion may necessitate repeated interventions, such as fluid drainage or surgery, further affecting emotional well-being and overall health, leading to a diminished quality of life.

Key Epidemiology Trends

The latest epidemiological trends in various diseases offer insights into the changing dynamics of global health. These trends reflect a combination of advancements in healthcare, shifts in population demographics, and the influence of environmental and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

lifestyle factors. Understanding these trends is critical for public health planning, resource allocation, and the development of targeted interventions. Here are five important trends that have emerged in recent years across different regions.

1. Rising Incidence of Non-Communicable Diseases (NCDs)

One of the most significant trends observed globally is the increasing prevalence of non-communicable diseases, such as cardiovascular diseases, diabetes, and certain types of cancer. With the growing prevalence of risk factors like obesity, high blood pressure, and physical inactivity, these conditions have become leading causes of death and disability worldwide. The aging population further compounds this trend, as many non-communicable diseases are more common in older adults. Preventive measures, including lifestyle modifications and early screening, have been identified as crucial strategies to combat this growing issue.

2. Increasing Cancer Incidence

The incidence of various cancers continues to rise globally, largely due to an aging population, improved diagnostic technologies, and lifestyle factors such as tobacco use, unhealthy diets, and exposure to carcinogens. Lung, breast, and colorectal cancers are among the most common, and the number of new cases is projected to increase in the coming decades. Early detection through screening programs and advancements in treatment, such as immunotherapy and targeted therapy, are helping improve survival rates, but the burden on healthcare systems is escalating.

3. Mental Health Disorders and Their Rising Prevalence

Another emerging trend is the rising prevalence of mental health disorders, including depression, anxiety, and stress-related disorders. Factors such as the increasing social isolation, urbanization, economic stress, and the impact of the COVID-19 pandemic have contributed to a surge in mental health problems. This trend is particularly evident among younger populations, including adolescents and young adults. Mental health services are now a priority in many healthcare systems, with a focus on providing accessible care and addressing the stigma surrounding mental illness.

4. The Burden of Infectious Diseases in Low-Income Regions

While non-communicable diseases dominate the health burden in developed countries, infectious diseases continue to be a major concern in low-income regions, particularly in Sub-Saharan Africa and parts of Asia. Malaria, tuberculosis, and HIV/AIDS remain prevalent, and their incidence rates are influenced by factors such as poverty, lack of healthcare access, and insufficient vaccination coverage. Efforts to control these diseases through improved healthcare infrastructure, vaccination programs, and targeted interventions are ongoing, but the progress remains slow, and these diseases continue to impact the health of millions.

5. Impact of Environmental Factors on Health

Environmental factors such as air pollution, climate change, and exposure to hazardous chemicals are increasingly recognized as significant contributors to the global burden of disease. Diseases related to poor air quality, such as respiratory infections, asthma, and chronic obstructive pulmonary disease, are on the rise, particularly in urban areas with high levels of pollution. Climate change is also linked to the spread of vector-borne diseases like malaria and dengue fever. The global effort to combat climate change is closely tied to improving health outcomes by reducing exposure to these environmental risks.

Analysis By Region

The epidemiology of pleural effusion varies across countries and regions due to differences in healthcare infrastructure, socioeconomic factors, cultural attitudes towards pain, and access to pain management therapies. Understanding these variations is essential for developing targeted interventions and improving patient outcomes.

Key regions include:

- The United States
- Germany
- France
- Italy
- Spain

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

-□The United Kingdom

-□Japan

-□India

These regions exhibit distinct epidemiological trends, reflecting the unique challenges and opportunities within their healthcare systems.

The epidemiology of pleural effusion differs considerably across countries, influenced by factors such as the prevalence of underlying conditions (including lung cancer, pneumonia, tuberculosis, and heart failure), healthcare accessibility, diagnostic procedures, environmental influences, and lifestyle habits. In the United States, approximately 1.5 million individuals are affected by pleural effusion each year.

Key Questions Answered

- 1.□How do socioeconomic factors influence the prevalence and outcomes of specific diseases in different regions?
- 2.□What are the key environmental determinants contributing to the rise of respiratory diseases in urban areas?
- 3.□How does access to healthcare impact the early diagnosis and treatment outcomes of chronic diseases?
- 4.□How do genetic and lifestyle factors interact to affect the incidence of non-communicable diseases across various populations?
- 5.□What role do vaccination programs play in altering the epidemiological trends of infectious diseases in developing countries?
- 6.□How has the increasing global mobility influenced the spread of emerging infectious diseases?
- 7.□In what ways do cultural differences impact the epidemiology of mental health disorders?
- 8.□How do changes in population demographics, such as aging populations, affect the incidence of age-related diseases like dementia and heart disease?
- 9.□What are the long-term epidemiological consequences of the COVID-19 pandemic on global health systems?
- 10.□How do environmental changes, like climate change and air pollution, affect the incidence of cardiovascular and respiratory diseases?

Scope of the Report

- The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of pleural effusion based on several factors.
- The pleural effusion epidemiology forecast report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India)
- The report helps to identify the patient population, the unmet needs of pleural effusion are highlighted along with an assessment of the disease's risk and burden.

Table of Contents:

- 1 Preface
 - 1.1 Introduction
 - 1.2 Objectives of the Study
 - 1.3 Research Methodology and Assumptions
- 2 Executive Summary
- 3 Pleural Effusion Market Overview - 8 MM
 - 3.1 Pleural Effusion Market Historical Value (2018-2024)
 - 3.2 Pleural Effusion Market Forecast Value (2025-2034)
- 4 Pleural Effusion Epidemiology Overview - 8 MM
 - 4.1 Pleural Effusion Epidemiology Scenario (2018-2024)
 - 4.2 Pleural Effusion Epidemiology Forecast
- 5 Disease Overview
 - 5.1 Signs and Symptoms

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | |
|--|--|
| 5.2 Causes | |
| 5.3 Risk Factors | |
| 5.4 Guidelines and Stages | |
| 5.5 Pathophysiology | |
| 5.6 Screening and Diagnosis | |
| 6 Patient Profile | |
| 6.1 Patient Profile Overview | |
| 6.2 Patient Psychology and Emotional Impact Factors | |
| 7 Epidemiology Scenario and Forecast - 8 MM | |
| 7.1 Key Findings | |
| 7.2 Assumptions and Rationale | |
| 7.3 Pleural Effusion Epidemiology Scenario in 8MM (2018-2034) | |
| 8 Epidemiology Scenario and Forecast: United States | |
| 8.1 Pleural Effusion Epidemiology Scenario and Forecast in the United States (2018-2034) | |
| 9 Epidemiology Scenario and Forecast: United Kingdom | |
| 9.1 Pleural Effusion Epidemiology Scenario and Forecast in United Kingdom (2018-2034) | |
| 10 Epidemiology Scenario and Forecast: Germany | |
| 10.1 Pleural Effusion Epidemiology Scenario and Forecast in Germany (2018-2034) | |
| 11 Epidemiology Scenario and Forecast: France | |
| 11.1 Pleural Effusion Epidemiology Scenario and Forecast in France | |
| 12 Epidemiology Scenario and Forecast: Italy | |
| 12.1 Pleural Effusion Epidemiology Scenario and Forecast in Italy (2018-2034) | |
| 13 Epidemiology Scenario and Forecast: Spain | |
| 13.1 Pleural Effusion Epidemiology Scenario and Forecast in Spain (2018-2034) | |
| 14 Epidemiology Scenario and Forecast: Japan | |
| 14.1 Pleural Effusion Epidemiology Scenario and Forecast in Japan (2018-2034) | |
| 15 Epidemiology Scenario and Forecast: India | |
| 15.1 Pleural Effusion Epidemiology Scenario and Forecast in India (2018-2034) | |
| 16 Patient Journey | |
| 17 Treatment Challenges and Unmet Needs | |
| 18 Key Opinion Leaders (KOL) Insights | |

Pleural Effusion Epidemiology Forecast 2025-2034

Market Report | 2025-05-12 | 150 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

| Select license | License | Price |
|----------------|---------------------|-----------|
| | Single User License | \$2699.00 |
| | Five User License | \$3739.00 |
| | Corporate License | \$4929.00 |
| | | VAT |
| | | Total |

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

| | | | |
|---------------|----------------------|-------------------------------|---|
| Email* | <input type="text"/> | Phone* | <input type="text"/> |
| First Name* | <input type="text"/> | Last Name* | <input type="text"/> |
| Job title* | <input type="text"/> | | |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/> |
| Address* | <input type="text"/> | City* | <input type="text"/> |
| Zip Code* | <input type="text"/> | Country* | <input type="text"/> |
| | | Date | <input type="text" value="2026-02-13"/> |
| | | Signature | <input type="text"/> |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com